These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Effects of plasma fibronectin on the healing of full-thickness skin wounds in streptozotocin-induced diabetic rats. Qiu Z; Kwon AH; Kamiyama Y J Surg Res; 2007 Mar; 138(1):64-70. PubMed ID: 17161431 [TBL] [Abstract][Full Text] [Related]
10. Ocular surface abnormalities related to type 2 diabetes are reversed by the opioid antagonist naltrexone. Zagon IS; Sassani JW; Immonen JA; McLaughlin PJ Clin Exp Ophthalmol; 2014 Mar; 42(2):159-68. PubMed ID: 23777539 [TBL] [Abstract][Full Text] [Related]
11. Blockade of the OGF-OGFr pathway in diabetic bone. Titunick MB; Lewis GS; Cain JD; Zagon IS; McLaughlin PJ Connect Tissue Res; 2019 Nov; 60(6):521-529. PubMed ID: 30931654 [No Abstract] [Full Text] [Related]
12. Naltrexone and insulin are independently effective but not additive in accelerating corneal epithelial healing in type I diabetic rats. Klocek MS; Sassani JW; McLaughlin PJ; Zagon IS Exp Eye Res; 2009 Nov; 89(5):686-92. PubMed ID: 19576213 [TBL] [Abstract][Full Text] [Related]
13. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review. McLaughlin PJ; Sassani JW; Klocek MS; Zagon IS Brain Res Bull; 2010 Feb; 81(2-3):236-47. PubMed ID: 19683562 [TBL] [Abstract][Full Text] [Related]
14. The diabetic rat as an impaired wound healing model: stimulatory effects of transforming growth factor-beta and basic fibroblast growth factor. Broadley KN; Aquino AM; Hicks B; Ditesheim JA; McGee GS; Demetriou AA; Woodward SC; Davidson JM Biotechnol Ther; 1989-1990; 1(1):55-68. PubMed ID: 2562644 [TBL] [Abstract][Full Text] [Related]
15. Ocular surface complications result from dysregulation of the OGF-OGFr signaling pathway in female diabetic rats. Purushothaman I; Zagon IS; Sassani JW; Mclaughlin PJ Exp Ther Med; 2021 Jul; 22(1):687. PubMed ID: 33986852 [TBL] [Abstract][Full Text] [Related]
16. Topical Naltrexone as Treatment for Type 2 Diabetic Cutaneous Wounds. Immonen JA; Zagon IS; McLaughlin PJ Adv Wound Care (New Rochelle); 2014 Jun; 3(6):419-427. PubMed ID: 24940556 [No Abstract] [Full Text] [Related]
17. Naltrexone, an opioid antagonist, facilitates reepithelialization of the cornea in diabetic rat. Zagon IS; Jenkins JB; Sassani JW; Wylie JD; Ruth TB; Fry JL; Lang CM; McLaughlin PJ Diabetes; 2002 Oct; 51(10):3055-62. PubMed ID: 12351447 [TBL] [Abstract][Full Text] [Related]
18. Antioxidant and anti-inflammatory potential of curcumin accelerated the cutaneous wound healing in streptozotocin-induced diabetic rats. Kant V; Gopal A; Pathak NN; Kumar P; Tandan SK; Kumar D Int Immunopharmacol; 2014 Jun; 20(2):322-30. PubMed ID: 24675438 [TBL] [Abstract][Full Text] [Related]
19. Topical Naltrexone Is a Safe and Effective Alternative to Standard Treatment of Diabetic Wounds. McLaughlin PJ; Cain JD; Titunick MB; Sassani JW; Zagon IS Adv Wound Care (New Rochelle); 2017 Sep; 6(9):279-288. PubMed ID: 28894635 [No Abstract] [Full Text] [Related]
20. Reepithelialization of the human cornea is regulated by endogenous opioids. Zagon IS; Sassani JW; McLaughlin PJ Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):73-81. PubMed ID: 10634604 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]